- Trial phase
- Approved (FDA accelerated approval)
- Time to market
- Already FDA-approved (March 26, 2026); commercial launch underway
- Why 4/10
- KRESLADI is already FDA-approved (March 26, 2026) with no pending regulatory decision. The defining binary catalyst has passed. The stock's next hard catalysts are related to Rocket's pipeline (RP-A501 Danon disease data, RP-A701 BAG3 cardiomyopathy dosing), not KRESLADI itself.
KRESLADI's approval and the $180M PRV sale provide a cash runway into Q2 2028, but the drug is an ultra-orphan gene therapy with a "minimal viable launch", not a major revenue generator. Watch the company's cardiovascular pipeline (RP-A501 for Danon disease, RP-A701 for BAG3 cardiomyopathy) for future catalysts. RCKT carries heavy short interest (~25.5% of float), a squeeze risk if pipeline data hits, but the clinical hold history on RP-A501 adds risk.
Price Chart
Executive Summary
KRESLADI (marnetegragene autotemcel) is Rocket Pharmaceuticals' first FDA-approved product, a one-time gene therapy for severe leukocyte adhesion deficiency type I (LAD-I), an ultra-rare pediatric immune disorder. It was approved via accelerated approval on March 26, 2026, after a Phase 1/2 trial showed 100% survival. The company then sold its rare pediatric disease Priority Review Voucher for $180M in April 2026, extending its cash runway. However, with an ultra-orphan patient population (~1 in 1M), Rocket plans only a 'minimal viable launch,' and the stock has declined ~27% since approval to ~$3.45, weighed by clinical holds on the key pipeline drug RP-A501. The defining binary for KRESLADI has passed; future value depends on pipeline execution.
How It Works
KRESLADI is a one-time gene therapy made from the patient's own blood stem cells. The cells are collected, genetically modified in a lab to carry a working copy of a crucial gene (ITGB2), and infused back into the patient. This enables their white blood cells to produce a protein called CD18, which is essential for immune cells to leave the bloodstream and reach infection sites. Without it, children suffer fatal, recurrent infections.
Trial Status
Approved under FDA accelerated approval based on a global Phase 1/2 study that demonstrated 100% overall survival at 12 months post-infusion and beyond for all 9 enrolled patients. All primary and secondary endpoints were met. A confirmatory study is ongoing to verify clinical benefit.
The Two-Sided Case
Upcoming Catalysts
- RP-A501 Phase 2 pivotal trial data for Danon disease (next major pipeline catalyst)
- First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy (mid-2026)
- KRESLADI confirmatory study data readouts (ongoing, no hard date set)
- Quarterly earnings reports, KRESLADI launch metrics and commercial traction
Source Filing
The SEC filing that triggered this drug report: